Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PEPD | P12955 | 2/20 | 0.42 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874672 | 1.00 | FKBP1A (0.64) | FKBP1APOLBALOX5PEPDXPNPEP1 | |
| SCHEMBL2006947 | 0.95 | FKBP1A (0.58) | FKBP1APOLBALOX5PEPDXPNPEP1 | |
| SCHEMBL7245076 | 0.87 | FKBP1A (0.50) | FKBP1APOLBALOX5PEPDXPNPEP1 | |
| SCHEMBL10034603 | 0.86 | FKBP1A (0.57) | FKBP1APOLB | |
| SCHEMBL1774605 | 0.86 | FKBP1A (0.58) | FKBP1APEPDLMNARAB9A | |
| SCHEMBL5833327 | 0.86 | FKBP1A (0.68) | FKBP1AALDH1A1 | |
| SCHEMBL611148 | 0.86 | FKBP1A (0.68) | FKBP1AALDH1A1 | |
| SCHEMBL4484566 | 0.84 | FKBP1A (0.56) | FKBP1APOLBALOX5PEPDXPNPEP1 | |
| SCHEMBL3061683 | 0.82 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1ALDH1A1 | |
| SCHEMBL5965365 | 0.82 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3007696-B1 | NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10167259-B2 | Allosteric inhibitors of proteasome and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160152567-A1 | NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152567-A1 | NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM (US) | 2016-06-02 | — | — | US | disclosed |
| US-7943775-B2 | to detect amyloid deposits prior to aggregation into plaques; labeled bifunctional compound binds to target protein and to chaperone protein; Alzheimer's; 1-[4-(carboxymethoxy)phenyl]-3-(3,4-dimethoxy-phenyl)-1-propanyl-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate isomers bind differently | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080085238-A1 | Small Molecules for Imaging Protein-Protein Interactions | The Government of the United States of America as represented (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1900726-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1626043-B1 | Heterocyclic thioesters | MGI GP INC (US) | 2007-12-12 | — | — | EP | disclosed |
| CN-1285575-C | Heterocyclic thioesters and ketones | GPI NIL HOLDING CO (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1083873-B1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | MGI GP INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1105112-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001038304-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL HOLDINGS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
| CN-1275977-A | Heterocyclic thioesters and ketones | GPI NIL HOLDING CO (US) | 2000-12-06 | — | — | CN | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000009108-A2 | COMPOSITIONS AND USES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| US-5990131-A | OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY | GPI NIL HOLDINGS INC. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5786378-A | FKBP TYPE IMMUNOPHILLINS FOR NERVOUS SYSTEM DISORDERS | GPI NIL HOLDINGS, INC. (US) | 1998-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085238-A1 | Small Molecules for Imaging Protein-Protein Interactions | HSPBP1, HSPA2, HSPA8 | FKBP1A 1547/4885POLB 4361/4885ALOX5 4857/4885 |
| US-20160152567-A1 | NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF | PSME3, PSMB1, PSMB2 | FKBP1A 1557/4885POLB 1061/4885ALOX5 3419/4885 |
| US-10167259-B2 | Allosteric inhibitors of proteasome and methods of use thereof | PSMC1, PSME3, PSMB1 | FKBP1A 1511/4885POLB 1046/4885ALOX5 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.